JP2004519475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004519475A5 JP2004519475A5 JP2002567137A JP2002567137A JP2004519475A5 JP 2004519475 A5 JP2004519475 A5 JP 2004519475A5 JP 2002567137 A JP2002567137 A JP 2002567137A JP 2002567137 A JP2002567137 A JP 2002567137A JP 2004519475 A5 JP2004519475 A5 JP 2004519475A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- pharmaceutical composition
- composition according
- antibody
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 49
- 239000005557 antagonist Substances 0.000 description 45
- 102000014150 Interferons Human genes 0.000 description 44
- 108010050904 Interferons Proteins 0.000 description 44
- 229940079322 interferon Drugs 0.000 description 44
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 25
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 208000023275 Autoimmune disease Diseases 0.000 description 17
- 108010047761 Interferon-alpha Proteins 0.000 description 14
- 102000006992 Interferon-alpha Human genes 0.000 description 14
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000002227 Interferon Type I Human genes 0.000 description 8
- 108010014726 Interferon Type I Proteins 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000003550 marker Substances 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- 102000001617 Interferon Receptors Human genes 0.000 description 4
- 108010054267 Interferon Receptors Proteins 0.000 description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000816 peptidomimetic Substances 0.000 description 4
- 238000001525 receptor binding assay Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 208000009388 Job Syndrome Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26054101P | 2001-01-09 | 2001-01-09 | |
| PCT/US2002/000343 WO2002067760A2 (en) | 2001-01-09 | 2002-01-08 | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009063336A Division JP2009132736A (ja) | 2001-01-09 | 2009-03-16 | 対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004519475A JP2004519475A (ja) | 2004-07-02 |
| JP2004519475A5 true JP2004519475A5 (enExample) | 2007-05-10 |
| JP4394350B2 JP4394350B2 (ja) | 2010-01-06 |
Family
ID=22989575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567137A Expired - Fee Related JP4394350B2 (ja) | 2001-01-09 | 2002-01-08 | 対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ |
| JP2009063336A Withdrawn JP2009132736A (ja) | 2001-01-09 | 2009-03-16 | 対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009063336A Withdrawn JP2009132736A (ja) | 2001-01-09 | 2009-03-16 | 対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7544357B2 (enExample) |
| EP (2) | EP2236156A3 (enExample) |
| JP (2) | JP4394350B2 (enExample) |
| KR (1) | KR100951409B1 (enExample) |
| CN (2) | CN100536919C (enExample) |
| AT (1) | ATE502648T1 (enExample) |
| AU (1) | AU2002246955B2 (enExample) |
| BR (1) | BR0206364A (enExample) |
| CA (1) | CA2433806C (enExample) |
| DE (1) | DE60239522D1 (enExample) |
| DK (1) | DK1351707T3 (enExample) |
| ES (1) | ES2363761T3 (enExample) |
| MX (1) | MXPA03006100A (enExample) |
| WO (1) | WO2002067760A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2236156A3 (en) * | 2001-01-09 | 2011-01-05 | Baylor Research Institute | Methods for treating and diagnosing Psoriasis |
| EP1701736A4 (en) * | 2003-12-24 | 2008-05-07 | Inst Medical W & E Hall | THERAPEUTIC AGENTS AND USES |
| EP1781705B1 (en) | 2004-06-21 | 2014-10-08 | Medarex, L.L.C. | Interferon alpha receptor i antibodies and their uses |
| AU2005274852B2 (en) * | 2004-07-19 | 2011-12-08 | The Johns Hopkins University | FLT3 inhibitors for immune suppression |
| NZ554065A (en) * | 2004-10-07 | 2010-12-24 | Univ Zuerich | Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis |
| CA2597265C (en) | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| CA2685147A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Auto-antibody markers of autoimmune disease |
| CA2878025C (en) | 2008-01-18 | 2018-12-11 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| HUE028958T2 (en) | 2008-02-08 | 2017-01-30 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| EP2279207B1 (en) | 2008-05-07 | 2015-09-09 | Argos Therapeutics, Inc. | Humanized antibodies against human interferon-alpha |
| CA2743590A1 (en) * | 2008-11-12 | 2010-05-20 | Yeda Research And Development Co. Ltd. | Diagnosis of multiple sclerosis |
| CN101812119B (zh) * | 2009-02-25 | 2012-02-01 | 上海荣盛生物药业有限公司 | 与免疫抗体相结合的多肽及其应用 |
| MX2013000917A (es) | 2010-07-23 | 2013-07-05 | Harvard College | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| KR20140034124A (ko) | 2010-12-06 | 2014-03-19 | 티에이치디 에스.피.에이. | 암종의 진단방법 및 그의 용도 |
| US9823246B2 (en) | 2011-12-28 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon |
| CN109536446B (zh) * | 2012-02-10 | 2022-08-02 | 医疗法人社团博心厚生会 | 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法 |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| KR101536697B1 (ko) * | 2013-11-29 | 2015-07-14 | 아주대학교산학협력단 | 베체트병 진단용 조성물 |
| EP4428251A3 (en) | 2014-09-11 | 2024-12-18 | Immunis.AI, Inc. | Methods of detecting prostate cancer |
| EP3215846B1 (en) | 2014-11-05 | 2020-03-11 | Nirmidas Biotech, Inc. | Metal composites for enhanced imaging |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| JP7374091B2 (ja) | 2017-08-22 | 2023-11-06 | サナバイオ， エルエルシー | 可溶性インターフェロン受容体およびその使用 |
| KR20250139415A (ko) * | 2018-02-14 | 2025-09-23 | 호라이즌 테라퓨틱스 아일랜드 디에이씨 | 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도 |
| US12123881B2 (en) * | 2018-04-20 | 2024-10-22 | Unm Rainforest Innovations | Rap1-Gtp, Rac1-GTP and FMS-like tyrosine kinase 3 ligand (FLT3-L) as biomarkers for early detection of sepsis |
| WO2019241158A1 (en) * | 2018-06-11 | 2019-12-19 | Univerity Of Washington | Compositions and methods for treating inflammatory diseases |
| CN113238061B (zh) * | 2021-07-09 | 2021-10-01 | 中南大学湘雅医院 | 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用 |
| CN115032396B (zh) * | 2022-06-29 | 2025-02-21 | 深圳市康尔诺生物技术有限公司 | 一种用于预测或判断受试者的肿瘤免疫治疗效果的生物标志物及其应用 |
| CN115678982A (zh) * | 2022-09-09 | 2023-02-03 | 中山大学 | 一种用于慢性自身免疫病诊断和/或病种判断的试剂盒 |
| EP4605001A1 (en) * | 2022-10-20 | 2025-08-27 | GlaxoSmithKline Intellectual Property (No.3) Limited | Antigen binding proteins |
| WO2025015182A2 (en) * | 2023-07-12 | 2025-01-16 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Compositions and methods for treatment of autoimmunity |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4423147A (en) * | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
| GR81946B (enExample) * | 1980-09-25 | 1984-12-12 | Genentech Inc | |
| US4414150A (en) | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4824432A (en) * | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
| US4605394A (en) * | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
| US4362155A (en) | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
| DE3211263A1 (de) * | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
| US4678751A (en) * | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US5096705A (en) * | 1981-10-19 | 1992-03-17 | Genentech, Inc. | Human immune interferon |
| US5582824A (en) * | 1981-10-19 | 1996-12-10 | Genentech, Inc. | Recombinant DES-CYS-TYR-CYS human immune interferon |
| US5827694A (en) * | 1982-03-08 | 1998-10-27 | Genentech, Inc. | DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides |
| US4534906A (en) * | 1982-11-01 | 1985-08-13 | Genentech, Inc. | Removal of impurities from human leukocyte interferon preparations |
| US5831023A (en) * | 1982-11-01 | 1998-11-03 | Genentech, Inc. | Recombinant animal interferon polypeptides |
| EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
| US5082658A (en) | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
| FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
| US4650674A (en) | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
| US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
| US4828830A (en) * | 1986-01-24 | 1989-05-09 | Genentech, Inc. | Method and composition for prophylaxis and treatment of viral infections |
| JPS6330426A (ja) | 1986-07-25 | 1988-02-09 | Mitsubishi Chem Ind Ltd | 自己免疫性疾患治療薬 |
| US4851219A (en) * | 1986-11-18 | 1989-07-25 | Genentech, Inc. | Method for the treatment of chronic myelogenous leukemia |
| US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4944941A (en) * | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
| US5254678A (en) * | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
| AU2844889A (en) | 1988-01-22 | 1989-07-27 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US5889151A (en) * | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| WO1992018626A1 (fr) * | 1991-04-17 | 1992-10-29 | Laboratoire Europeen De Biotechnologie | POLYPEPTIDES HYDROSOLUBLES AYANT UNE HAUTE AFFINITE POUR LES INTERFERONS α ET $g(b) |
| US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
| WO1993004699A1 (en) * | 1991-08-30 | 1993-03-18 | Genentech, Inc. | Therapeutic method for iddm |
| US5248499A (en) * | 1991-10-07 | 1993-09-28 | Genentech, Inc. | Control of microbial infections in transplant patients |
| EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| US5821078A (en) | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US6630143B1 (en) * | 1993-05-24 | 2003-10-07 | Immunex Corporation | Antibodies against flt3 ligand |
| CZ307995A3 (en) * | 1993-05-24 | 1996-10-16 | Immunex Corp | Ligands for flt3 receptors |
| CA2171955A1 (en) | 1993-09-17 | 1995-03-23 | Michael G. Tovey | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
| US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US5780027A (en) * | 1995-07-14 | 1998-07-14 | Meiogen Biotechnology Corporation | Methods of treatment of down syndrome by interferon antagonists |
| IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
| US6713609B1 (en) | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
| US5859183A (en) * | 1997-02-13 | 1999-01-12 | The Rockefeller University | Altered telomere repeat binding factor |
| US20030018174A1 (en) * | 1997-10-06 | 2003-01-23 | Genentech, Inc. | Monoclonal antibodies to IFNAR2 |
| ATE428769T1 (de) | 1997-10-27 | 2009-05-15 | Univ Rockefeller | Methode und zusammensetzung zur herstellung von reifen dendritischen zellen |
| ZA9811070B (en) * | 1997-12-08 | 2000-07-03 | Genentech Inc | Type I interferons. |
| US6299869B1 (en) * | 1997-12-08 | 2001-10-09 | Genentech, Inc. | Human interferon-epsilon: a type I interferon |
| US6291661B1 (en) * | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| ATE302848T1 (de) | 1999-12-30 | 2005-09-15 | Imclone Systems Inc | Stammzellen schutzfaktor und verwandte methoden und produkte |
| GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
| US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| WO2002024874A2 (en) * | 2000-09-21 | 2002-03-28 | Schering Corporation | Methods for preparing interferon producing dentitric cells |
| EP2236156A3 (en) * | 2001-01-09 | 2011-01-05 | Baylor Research Institute | Methods for treating and diagnosing Psoriasis |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| FR2822845B1 (fr) | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
| US6554512B2 (en) * | 2001-04-26 | 2003-04-29 | Zih Corp. | Printer for printing deformable flat supports and its loader |
| MXPA05011406A (es) | 2003-04-23 | 2005-12-12 | Medarex Inc | Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1). |
| DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| NZ554065A (en) | 2004-10-07 | 2010-12-24 | Univ Zuerich | Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis |
-
2002
- 2002-01-08 EP EP10163628A patent/EP2236156A3/en not_active Withdrawn
- 2002-01-08 DE DE60239522T patent/DE60239522D1/de not_active Expired - Lifetime
- 2002-01-08 DK DK02714705.7T patent/DK1351707T3/da active
- 2002-01-08 BR BR0206364-6A patent/BR0206364A/pt not_active Application Discontinuation
- 2002-01-08 KR KR1020037009204A patent/KR100951409B1/ko not_active Expired - Lifetime
- 2002-01-08 WO PCT/US2002/000343 patent/WO2002067760A2/en not_active Ceased
- 2002-01-08 MX MXPA03006100A patent/MXPA03006100A/es active IP Right Grant
- 2002-01-08 US US10/466,023 patent/US7544357B2/en not_active Expired - Lifetime
- 2002-01-08 JP JP2002567137A patent/JP4394350B2/ja not_active Expired - Fee Related
- 2002-01-08 AU AU2002246955A patent/AU2002246955B2/en not_active Expired
- 2002-01-08 CN CNB028035569A patent/CN100536919C/zh not_active Expired - Lifetime
- 2002-01-08 CN CN200910160480A patent/CN101612402A/zh active Pending
- 2002-01-08 AT AT02714705T patent/ATE502648T1/de active
- 2002-01-08 US US10/042,644 patent/US20020160974A1/en not_active Abandoned
- 2002-01-08 EP EP02714705A patent/EP1351707B9/en not_active Revoked
- 2002-01-08 ES ES02714705T patent/ES2363761T3/es not_active Expired - Lifetime
- 2002-01-08 CA CA2433806A patent/CA2433806C/en not_active Expired - Lifetime
-
2009
- 2009-03-16 JP JP2009063336A patent/JP2009132736A/ja not_active Withdrawn
- 2009-05-04 US US12/435,267 patent/US20090263474A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004519475A5 (enExample) | ||
| CA2433806A1 (en) | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays | |
| Saschenbrecker et al. | Serological diagnosis of autoimmune bullous skin diseases | |
| Wadhwa et al. | Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals | |
| Tahara et al. | A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders | |
| Corti et al. | Tumor Necrosis Factor (TNF) α quantification by ELISA and bioassay: Effects of TNFα-soluble TNF receptor (p55) complex dissociation during assay incubations | |
| Richalet-Sécordel et al. | Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation | |
| EP2354792A1 (en) | Method for detecting anti-drug antibodies | |
| JP2013163673A5 (enExample) | ||
| CA2434512A1 (en) | Marker for inflammatory conditions | |
| Suh et al. | Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review | |
| Thorpe et al. | Current methods for detecting antibodies against erythropoietin and other recombinant proteins | |
| RU2011118477A (ru) | Способы и композиции для диагностики и лечения аутоиммунной болезни, возникающей вследствие рассеянного склероза | |
| CN110546506B (zh) | 改进的免疫原性测定法 | |
| Kakkar et al. | Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor | |
| Torres et al. | Hypersensitivity reactions to beta-lactams | |
| Thorpe et al. | Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures | |
| Liparoto et al. | Biosensor analysis of the interleukin‐2 receptor complex | |
| US9927443B2 (en) | Risk assessment for therapeutic drugs | |
| JP2022545312A (ja) | 関節リウマチの診断及び処置の方法 | |
| Takacs et al. | Detection and characterization of antibodies to PEG-IFN-alpha2b using surface plasmon resonance | |
| Oh et al. | Clinical utility and cross-reactivity of insulin and C-peptide assays by the Lumipulse G1200 system | |
| Groome et al. | Enzyme immunoassays for inhibins, activins and follistatins | |
| US20060003384A1 (en) | Detection of measurement of antibodies to antigenic proteins in biological tissues or samples | |
| Myler et al. | Biotherapeutic bioanalysis: a multi-indication case study review |